LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback